Metabolic Syndrome
New data presented for Crestor in patients with metabolic syndrome
Published in Drug Week, October 8th, 2004
New data presented from the COmparative study with rosuvastatin in subjects with METabolic Syndrome (COMETS) showed that at the 20mg dosages AstraZeneca's (AZN) Crestor (rosuvastatin calcium) reduced LDL or "bad" cholesterol 49% and raised HDL or "good" cholesterol by more than 10%, a statistically significant finding compared to another commonly prescribed statin, atorvastatin, in patients with metabolic syndrome.
COMETS, presented at the 40th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Munich, Germany, is the first international prospective study of statin treatment in people with the metabolic syndrome.
"The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2004-10-08)
More Articles from Drug Week
- ADHD
FDA approves Methylin Chewable Tablets, Methylin Oral Solution for ADHD - Breast Cancer
Hedgehog signaling pathway is new therapeutic target for breast cancer - Smallpox
FDA clears IND for an attenuated smallpox vaccine candidate - Tremor
Agilect reduced tremor and severity of "off" time in Parkinson patients - ADHD
11.5% of Biodyne acquired by technology company - ADHD
Atomoxetine is novel treatment for attention deficit-hyperactivity disorder - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
